Stocks
Opus Genetics, Inc.IRD
NASDAQHealthcareBiotechnology$3.82
Price as of · delayed, not real-time
A clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases and other ocular disorders. Its lead candidates target genetic forms of blindness, and investors track the stock for its pipeline catalysts and potential in the ophthalmic gene therapy space.
52W Range: $1.70-$7.07
Congressional Interest in Opus Genetics, Inc. (IRD)
No congressional trades have been disclosed for Opus Genetics, Inc. (IRD) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IRD?
No congressional trades found for this stock.